ElectromeElectrome home
Buy ActiPatch®
Electrome · Evidence

Chronic Pain

Long-term studies and registries of wearable pulsed shortwave therapy for chronic pain.

publication

Meta-analysis of Clinical Efficacy of Pulsed Radio Frequency Energy Treatment

Synthesis of clinical PRFE evidence across postoperative recovery, chronic pain, wound healing, and musculoskeletal indications.

View source
publication

A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy

Six-month prospective study of 240 chronic pain patients (mean baseline pain 8.2/10, average duration 6.5 years) using wearable pulsed shortwave therapy.

View source
publication

ActiPatch: Can It Be a Tool to Empower Chronic Pain Patients?

Clinical commentary on the role of over-the-counter (OTC) pulsed shortwave therapy in chronic pain self-management and opioid-sparing care.

View source
publication

UK Registry Study of an over-the-counter (OTC) Chronic Pain Therapy

Real-world UK registry of chronic pain sufferers using wearable over-the-counter (OTC) pulsed shortwave therapy, reporting patient-reported outcome improvements outside the trial setting.

View source
Educational summary only. Not medical advice. Individual results vary. Consult a qualified healthcare provider before making treatment decisions. ActiPatch® is FDA-cleared (K192234) for musculoskeletal pain; RecoveryRx® is FDA-cleared (K190251) for adjunctive treatment of postoperative pain. Study outcomes such as edema reduction are evidence findings, not additional cleared indications. Both devices are developed and manufactured by BioElectronics Corporation and marketed by Electrome under an exclusive license.